<SEC-DOCUMENT>0001140361-13-038870.txt : 20131017
<SEC-HEADER>0001140361-13-038870.hdr.sgml : 20131017
<ACCEPTANCE-DATETIME>20131017084923
ACCESSION NUMBER:		0001140361-13-038870
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20131017
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131017
DATE AS OF CHANGE:		20131017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				900300868
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		131155469

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		678-384-6720

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>MIMEDIX GROUP, INC 8-K 10-17-2013
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Thomson Reuters Accelus
    Document created using Disclosure Solutions PROFILE 2.2.2.0
    Copyright 1995 - 2013 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; BORDER-TOP: black 4px solid">
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 14pt">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 14pt">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 12pt">Washington, D.C. 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Date of Report (date of earliest event reported): October 17, 2013</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 24pt; FONT-WEIGHT: bold">MIMEDX GROUP, INC.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Exact name of registrant as specified in charter)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Florida</div>
</td>
<td style="WIDTH: 33.83%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52491</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">26-2792552</div>
</td>
</tr>

<tr>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</div>
</td>
<td style="WIDTH: 33.83%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Commission File Number)</div>
</td>
<td style="WIDTH: 33.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(IRS Employer Identification No.)</div>
</td>
</tr>
</table>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1775 West Oak Commons Ct, NE</div>
</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">30062</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Marietta, GA</div>
</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Zip Code)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Address of principal executive offices)</div>
</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top"></td>
</tr>
</table>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(770) 651-9100</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">(Registrant&#8217;s telephone number, including area code)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 27pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 27pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 27pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 27pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Wingdings; FONT-SIZE: 10pt">o</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<hr style="BORDER-BOTTOM: black 4px solid; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; BORDER-TOP: black 1px solid">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; CLEAR: both" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 212.7pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"></div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 71px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 2.02</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Results of Operations and Financial Conditions.</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 18pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">On October 16, 2013, MiMedx Group, Inc. (&#8220;MiMedx&#8221; or the &#8220;Company&#8221;) issued a press release announcing that the Company&#8217;s third quarter revenue of approximately $16.1 million slightly exceeds the $16.0 million high end of its revenue guidance range for that quarter. &#160;The Company also increased its guidance for the lower end of its full year 2013 revenue range. MiMedx reported that it now expects the Company's 2013 full year revenue to be in the range of $57 million to $60 million. &#160;</font>A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">Item 9.01</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Financial Statements and Exhibits<a name="_GoBack"><!--Anchor--></a></td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72px"></td>
<td style="WIDTH: 24px; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(c)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">Exhibits</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 3.66%; VERTICAL-ALIGN: bottom; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: medium none; WIDTH: 85.64%; VERTICAL-ALIGN: bottom; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 3.66%; VERTICAL-ALIGN: bottom; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 85.64%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BACKGROUND-COLOR: #cceeff; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt"><a href="ex99_1.htm">99.1</a></div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BACKGROUND-COLOR: #cceeff; WIDTH: 3.66%; VERTICAL-ALIGN: bottom; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BACKGROUND-COLOR: #cceeff; WIDTH: 85.64%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">MiMedx Group, Inc. Press Release, dated October 16, 2013</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt" id="DSPFPageNumberArea">2</div>

<hr style="PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; CLEAR: both" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">SIGNATURES</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 50%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MIMEDX GROUP, INC.</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 12%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 50%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">&#160;</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none" colspan="2"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 12%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 50%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div>Dated:<font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &#160;</font>October 17, 2013</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 3%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">By:</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: medium none; WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -27.35pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 27.35pt; FONT-SIZE: 10pt">/s/: Michael J. Senken</div>
</td>
<td style="BORDER-LEFT: medium none; WIDTH: 12%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
</tr>

<tr>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 50%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">&#160;</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 3%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -27.35pt; FONT-FAMILY: ''Times New Roman'', Times, serif; MARGIN-LEFT: 27.35pt; FONT-SIZE: 10pt">Michael J. Senken, Chief Financial Officer</div>
</td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 12%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none"></td>
</tr>
</table>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, Serif; FONT-SIZE: 8pt">3</div>
</div>

<div>
<hr style="HEIGHT: 2px; COLOR: #000000" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Thomson Reuters Accelus
    Document created using Disclosure Solutions PROFILE 2.2.2.0
    Copyright 1995 - 2013 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="HEIGHT: 4px; COLOR: #000000" noshade="noshade">
</div>

<div style="FONT-WEIGHT: bold">Exhibit 99.1</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: right"><img src="image00003.jpg"></div>

<div style="TEXT-ALIGN: right">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 12px">
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRESS RELEASE</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTACT: &#160;MICHAEL SENKEN</div>
</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PHONE: &#160;(770) 651-9100</div>
</td>
</tr>
</table>

<div>
<div>&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<table style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: medium none; WIDTH: 100%; VERTICAL-ALIGN: top; BORDER-TOP: medium none; BORDER-RIGHT: medium none">
<div style="TEXT-ALIGN: center">MIMEDX TO EXCEED HIGH END OF THIRD QUARTER GUIDANCE </div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</div>

<div><font style="FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Marietta, Georgia, October 16, 2013</font>, (PR Newswire) -- MiMedx Group, Inc. &#160;(NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company will exceed the $16.0 million high end of its revenue guidance range for the third quarter of 2013, marking the &#160;8<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> consecutive quarter in which MiMedx has met or exceeded its revenue guidance.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The Company&#8217;s third quarter of 2013 revenue of approximately $16.1 million represents an increase of more than 100% over third quarter of 2012, and nearly a 150% increase over its revenue for the nine months ended September 30, 2012.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">The Company also updated its revenue guidance for the full year of 2013. &#160;At the end of the second quarter, MiMedx increased the lower end of its full year 2013 revenue range from $50 million to $54 million. MiMedx has now increased the lower end of its 2013 full year revenue guidance to $57 million with the upper end of the guidance remaining at $60 million.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About MiMedx</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">MiMedx&#174; is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. &#8220;<font style="FONT-STYLE: italic; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Innovations in Regenerative Biomaterials"</font> is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix&#174; and CollaFix&#8482;, and our tissue technologies, AmnioFix&#174; and EpiFix&#174;. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION&#174; process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx&#174; is the leading supplier of amniotic tissue, having supplied over 190,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="image00002.jpg"></div>

<div><br>
</div>

<div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 8pt;"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">MiMedx Group, Inc. &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">| </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">1775 West Oak Commons Ct NE &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;Marietta, GA 30062 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;770.651.9100 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;Fax 770.218.6195 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">www.mimedx.com</font></div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; CLEAR: both" id="DSPFPageBreak" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Safe Harbor Statement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">This press release includes statements that look forward in time or that express management&#8217;s beliefs, expectations or hopes. &#160;Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. &#160;These statements include, but are not limited to, the revenue goals for 2013. These statements are based on current information and belief, and are not guarantees of future performance. &#160;Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements are that 2013 revenue will be below expectations, that the approval of the three remaining Medicare Contractors will &#160;be delayed or the level of reimbursement will be less than anticipated, and the risk factors detailed from time to time in the Company&#8217;s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company&#8217;s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 8pt;"><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">MiMedx Group, Inc. &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">| </font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">1775 West Oak Commons Ct NE &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;Marietta, GA 30062 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;770.651.9100 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;Fax 770.218.6195 &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">|</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif"> &#160;</font><font style="FONT-FAMILY: ''Times New Roman'', Times, serif">www.mimedx.com</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: ''Times New Roman'', Times, serif; FONT-SIZE: 10pt">
<hr style="HEIGHT: 2px; COLOR: #000000" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"``A`)(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#ZIJCK=^NF
M:3=7C_\`+)"0/5NP_/%7JQ?$VCR:U':6QE"6:R^9<*"0S@=`#]:`*/@K4+^7
M[58:TQ:^BVS`D8RCC(_(\5"?&L:Q/.^F7@M(YC!).,%5(./J:LVOAA=-UJUO
MM-GDV@-'<+/*SET/3!/H:A/AFY/AJZTWSX?-FNC.'P=H&\-CZ\4P+5MXG62:
MZAN+"YM98;<W2++C]X@[\=#4.F^+4O+BP273[JVAO>(9GP59O3CG\:LZEHDU
MUJTETDL:HU@]H%(.=S=_I4">'[A;;P]'YT6=-<-(<'Y^,<4`5M,\0QVNFR.Y
MO;RXEO)(887*M(Q'88X"CWJS-KYNM)U:/R9[#4;6W:0Q28W*,'#`C@U5A\*W
M4-JC0W<4=_!=R7,,FTLF'ZJPJS'H%Y+'JEQ?W,,NHWEN;=?+4K'&N.!Z]:`*
M1DLFL))TN]4FGB165I2P,;%@-RE@!WZ=Q6G'K%TJ/920!M7C=4VJ/D=2?];[
M+C.?0\5?U2QDN]':TC91(0@R>G#`G^54+S2;Z>7[<MQ&NHQ3;H!SL6/H8SW.
M1R?>D!T%5]1=H]/N7C.UUB9E/H0#5@9P,\&H;R(SV<\*D!I(V0$]!D8H`XCP
MCK#SB.>ZU:^N9Q`\CVSP;8\@9X?']:TK;QBDD%O=3Z9>06$Q"_:6P54DX]<X
MSWHTW3M8TS1WM+N>QDLH;9T`C1@Y^4XY/%9FAZ-J>J^&].MKB]A&E,JNR"(B
M4@'.S/3'O3`LW.I.8-8V75\!%J$<3'<"44L`1'@9QBK#>4RPOIT]]]M:811S
M708;?E)P0P&Y3CD?C4\/AZXC?4#YT6+B^CNE'/RJK`X/OQ6QJ=K)<O:/"4S!
M-YI#'K\K#'ZT`4K+69KUX(8K8I<K(4NT;I#@<\]\\;?45MU@PZ1>07MK?+<J
M]X<K=[LA94)S@?[O;VK>I`%%%%`!16'KUG?W5[;-92-$B+M,B,`R[G3<0#WV
M!L?6LI;/Q,D0D%S(TJJ4$;.A&-G7IRVX]>GR^];1I*2OS(PE6<7;E;.QHKCU
MM?$R1.(IV*^6TD?FNC.&!;:A.,$D%23T^7%0#2=<FF1Y9;S@817N5*A?-&0X
M`^;Y`.GJ:KV"ZR1/UB72#.WHKC19>)9;=\W,\+$%\&2,MYFW'4#`0L<@>B^]
M7UM]7DL[Y9@[/+=+Y8D=>(MPSP.!QD>_7BI=%+[2*5=O[+.CHKEX]/UE]&U&
MWN;B22>X1$1G93L+`>81C'`R<#_9]ZRH]/\`$&E1R>1(8[:".615B"E9');^
M'J!C:0`#C\ZI44_M(EUY*WN.QWM%</91^)+@6\L4MTEM^\D59BOF$Y.U7SC@
M@#M_$?2IUL?$L=U;Q_;)9+97WM(2A=B%3@]/E)#\=LT.@D[.2!8AM74&=C17
M'-8^(P\*"XN'Q$&>3SD"[RC%EQC/WMH&.`.:2RTO7K58UMYYMKX1VN)5=D54
M0@Y[DL'7VW9H]BOYD'MY?R,[*BN0-CK<WA6>&^:2>]N)4+I\GR)E=^WG!'!X
M)[U5BTKQ!;VL4,&Z+$8C!BD4%6^9@3G/RY;E1_=`'%"H1_F0.O)6]QG<T5R3
M6/B+SVG6\EW%]PB+IY8^=N,8SC8%'7JWM54V'B1HTF$ET)T\QHUDN$(#>6H7
M<!P1GS"!VXH5!/[2!XAK[#.WHS7(Q:=KK0()[F60CR\)(R8/SEGW8SG`"J.:
MJBP\1R1F68W'G*K-'F6-F60JJDC&`!S)]!BA4%_,@>(E_(SN**AM4D6UA69F
M\P(H;+;N<<\XYHK"QT)DU%%%(84444`%%%%`!1110`4444`%%%%`!1110`44
-44`%%%%`!1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"``K`(D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#ZIHHHH`**
M**`"BBF/'YG#$[?0'&:`(+F_M[?B23+?W5&35*36)3_Q[Z==2CU*[16I'#''
M_JT5?H*?0!STFLZHOW=%F(_WO_K55D\5W%O_`,?>C72#U&?ZBNKHH`YFU\;:
M3*P69I;=N_F)D#\1FMVSOK6]3=:7$4R_[#`XJ*^TC3[Y2+JTAD]]N#^8YKE]
M0\"(K^?HMY+:S#D!F)'YCD?K3`[:BO/8_$>N^'95A\06K7%MG`F7K^#=#]#@
MUV&F:YIVI6WGVMU&5Z%6.UE/H0:+!<TJ*16#*&4@@\@@]:6D`4444`>;_&[7
M]4\/Z-ITVCW;6LDEP4=E4'(VDXY!KF?AYXWUV#QLFC^*KQIX[J-5B+*HVNP#
M(00!PP./Q%:7[1O_`"+^E?\`7TW_`*`:Q?BOH+IX8\-^);$%)K>V@BF9>H&T
M%&_`\?B*]W"PI2P\*<TKSNK];]#YW&5*T,3.I"3M#E=KZ6ZGNU>%>/\`QUKT
M_BO4K7PQ>M!9:;"QF**I!*_?;)![D+7:W7CV(?"W_A(491>21>0J>EQT(_`Y
M;Z5P?AGP^UE\'_$>M70)NM1A)1FZ^6&Z_B<G\JQP5!4FYUE?7E2?>^OW'1C\
M1*LHTZ$K:.3:[6T^\Z+P+XB\2:O\/KV]6X:[U%+SRPY5=RQ[5)P,`$\U%\2O
M$WB/1?"6A7"W36=_-*ZS%%4E@!QD$$`_2N,TTD?`W5<$C_B9IT_X!1XP.?A#
MX.SS^\F_F:Z5A(?6?::6YFK6\KG)+'3^J>SUORIWOKO8ZCX<>-=<C\:MHGBJ
M[:;[0@6(NJC:^-RXP!PP/\J]JKPKXO:');:7X?\`$]AE)HH88IF7J"%!C?\`
M/C\J[35_'L2_"T:_`RK=W$7DQH#]V<\$?A@GZ"N3%4%7Y*M%6YM&EW.S!XAX
M?VE&N[\OO)OJCA_'7CSQ!<^*-5A\,WS0:?IL1\PHJD':0&;)!_B.!7>_!G6M
M1UWPI+=:M<M<W`NG0.R@?*`N!P!ZFN`T'P\=-^"VOZK<J?M6I1JX+=1$'&W\
MSD_E6+8>(KS1/A(L&G2M!-?:C+&TJ'#*@120#V)R.?K794P].M2=*DE=24;_
M`"U.&EB:E"LJU9NSBY6OW>B/HN;4;*"3RY[RVCD_NO*H/Y$U95@RAE(*GD$'
M(-?.>@GX=1:1$NLV^K7FHR(&FF,;C#'KMP>@]>]7/AAXD?1O&%SIMA->7'A^
M997A6X4@IM0N#CL>"#Z]:XYY:U&3@W==U:_IJ=]/-4Y14TK2[.[7KH>\:A+9
MI`5U"2W6%^")F`5OSKR/XHZ)H^E:?;W]NX-E=3>28P=Z*2"<@^G%<_X`T5OB
M9XDU+4_$UQ--!!@^2KD<L3M4>B@#M4OQB\&VWA?2;671IIX]-GGVR6;R%T60
M*=KKGVW`U5/!4H5XT93?-Y+]>_R)J9A5GAY5X4UR^;_3M\ST+X=^*;%M-LM(
MFQ!)#&L4+%LK*H''/K_.N^KSK2_"MOKO@'0Y8]L-^ME'LE`X;Y>C?X]JP)/$
M^LI8-HCRH)1)Y)G+_,!TV[NF/]KTKS*JM-KS/6HRO3BTK:(]:M+IY[B>-X&C
M$9PK$_?JU7/^$/#D.A60RPEO)!^]EZ_@/:N@K,T/.OC5X<U3Q'H^GP:-;?:)
M8IR[C>JX&TCN175+HR7W@V+1]13`DLD@E7KM.P#\P?Y5MT5N\1/V<:?\KNCG
M6&@JDJC^TK,^<+7X9^+Y)H=*N82FDBZWNXF0J/X3(!G.=HKVKQGH\ESX"O\`
M2-(@#.;80P1`@<#&!D^PKI:*VK8^I6E&4DO=U,,/EU*A&48M^]IKV/$;+P1X
M@C^%.H:.]AC49;Y9DB\U>4&WG.<=C1XD\$>(+SX<>&M+M[#??6;RF>/S5&P$
MG'.<&O;J*O\`M*KS<UEO?YVL9_V51Y>6[VY?E>_8Q+K14U3PA_9%^N!+:+"X
MZ[6"CG\",_A7AFG_``S\6S7%II=_"8](6Z\QV$R%5S@,X&<Y(%?1U%9X?'5,
M.FHVU_#T-,3E]+$N+G?3\5YG,^.M'FO?`>H:5I,`:5H%BAB!"C`*X&3QT%>>
M:7\--2OOAL^EZ@B6>JPWCW-OO8,I!4#!(S@''Z"O::*5+&5*,.2/>Y=;`TJT
M^>?:WR/)]#UOQSH.EPZ9>^$6U![=!%%<13*`RC@9QG/'?BMWP7%XTO[R>X\6
M-:VVG.K!;)(U+G/8L.@`]\FN[HHGBE).T$F^O^5WH%/".#5ZDFETT_&RU/#]
M/\-^+/AYXCNKCP_8#5]+N/EV*P!*YRN1U##UY%.\<Z/XY\<6,,T^DQ6-O;O^
MZL?.!D<D<NQ/''3\:]NHK59C/G51Q7,NO],P>5PY'24VH/II_E<\_-IXDM_!
MNDZ/I]D8YDM4CN9?-4%2!@JO/YFC_A7D(\/F/S,ZK]_S,_+G^Y]/>O0**X93
J<I.3ZGHP@H145T.0\#+KMC']AUBT;[.H_=3>8K%/]D\]/2NOHHJ2C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
